Valneva SE revenue breakdown overview

Valneva SE revenue for the last year amounted to 175.57 M USD, the most of which — 175.55 M USD — came from its highest performing source at the moment, Development and Commercialization of Prophylactic Vaccines, the year earlier bringing 169.66 M USD. The greatest contribution to the revenue figure was made by United States — last year it brought Valneva SE 50.30 M USD, and the year before that — 36.38 M USD.